Citizens Jmp Cuts argenex (NASDAQ:ARGX) Price Target to $932.00

argenex (NASDAQ:ARGX) had its price objective reduced by Citizens Jmp from $944.00 to $932.00 in a research note released on Friday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Several other equities analysts have also recently commented on ARGX. Bank of America increased their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Morgan Stanley boosted their price objective on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Wedbush restated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Thursday, June 11th. Finally, Oppenheimer reduced their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,050.50.

argenex Price Performance

ARGX opened at $918.22 on Friday. argenex has a 12-month low of $587.37 and a 12-month high of $953.58. The stock has a market capitalization of $57.44 billion, a PE ratio of 35.26, a P/E/G ratio of 1.21 and a beta of 0.45. The firm’s fifty day moving average price is $868.28 and its 200 day moving average price is $815.22.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, equities research analysts forecast that argenex will post 26.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of institutional investors have recently modified their holdings of ARGX. AQR Capital Management LLC raised its stake in argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after acquiring an additional 122 shares during the period. NewEdge Advisors LLC lifted its holdings in argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after acquiring an additional 1,431 shares during the last quarter. Focus Partners Wealth boosted its stake in argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. boosted its stake in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after acquiring an additional 50 shares during the period. Institutional investors own 60.32% of the company’s stock.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.